journal
MENU ▼
Read by QxMD icon Read
search

Expert Review of Clinical Immunology

journal
https://www.readbyqxmd.com/read/28335641/corrigendum
#1
(no author information available yet)
No abstract text is available yet for this article.
March 24, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28277827/progress-and-prospects-for-the-use-and-the-understanding-of-the-mode-of-action-of-autologous-hematopoietic-stem-cell-transplantation-in-the-treatment-of-multiple-sclerosis
#2
Fredrika Collins, Majid Kazmi, Paolo A Muraro
A substantial proportion of patients with multiple sclerosis (MS) do not respond to pharmacological treatments and no currently approved therapy has been convincingly demonstrated to prevent or stop disease progression. With MS widely believed to be an auto-immune disease, immunoablative therapy followed by autologous haematopoietic stem cell transplantation (I/AHSCT) is being investigated as an alternative therapeutic option. Areas covered: With the results of phase III comparative trials only a few years away, this article reviews animal and clinical trials of I/AHSCT in the treatment of MS and discusses possible immunological mechanisms behind its action...
March 20, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28290219/2-crisaborole-topical-ointment-for-the-treatment-of-mild-to-moderate-atopic-dermatitis
#3
Alice C Cheape, Dedee F Murrell
Crisaborole 2% topical ointment is an anti-inflammatory, non-steroidal phosphodiesterase 4 inhibitor which is currently under investigation for its potential role in the treatment of atopic dermatitis and psoriasis. Areas covered: So far, 7 trials have been completed in atopic dermatitis. The 2% strength appeared to be the superior dosing regimen. Pruritus improved significantly within one week. The improvements in objective efficacy assessments in crisaborole-treated patients were also statistically significant compared to the vehicle...
March 14, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28277826/commonality-of-the-il-4-il-13-pathway-in-atopic-diseases
#4
Namita Gandhi, Gianluca Pirozzi, Neil Graham
Allergy results from an aberrant Type 2 inflammatory response, triggered by a wide range of environmental antigens (allergens) that lead to various immune responses, culminating in the production of immunoglobulin E (IgE). Two key cytokines, interleukin (IL)-4 and IL-13, are critical to the induction and perpetuation of the Type 2 response, and have been implicated in multiple atopic diseases. Area covered: This review summarizes recent milestone developments that have elucidated components of the pathogenesis of atopic diseases such as atopic dermatitis (AD), asthma, and chronic sinusitis with nasal polyposis (CSwNP)...
March 6, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28165883/the-role-of-il-23-in-the-treatment-of-psoriasis
#5
Lluís Puig
The IL-23/IL-17 axis is currently considered to be crucial in the pathogenesis of psoriasis. Human IL-23 is primarily produced by antigen-presenting cells and induces and maintains differentiation of Th17 cells and Th22 cells, a primary cellular source of proinflammatory cytokines such as IL-17 and IL-22, which mediate the epidermal hyperplasia, keratinocyte immune activation and tissue inflammation inherent in psoriasis. Agents that target the p40 subunit common to both IL-12 and IL-23 have shown robust clinical activity, but selectivity for IL-23p19 could offer advantages in efficacy and safety with respect to anti-p40 blockade...
February 6, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28165854/treatment-optimisation-in-multiple-sclerosis-how-do-we-apply-emerging-evidence
#6
Tjalf Ziemssen, Katja Thomas
No abstract text is available yet for this article.
February 6, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28165826/dupilumab-in-the-treatment-of-moderate-to-severe-atopic-dermatitis
#7
Magdalena Kraft, Margitta Worm
Atopic dermatitis is a common inflammatory skin disease with an increasing prevalence. Treatment of patients suffering from mild or moderate disease includes the use of emollients and topical glucocorticoids or topical calcineurin inhibitors. Patients with chronic and severe atopic dermatitis where topical therapy is usually insufficient require the use of systemic immunosuppressive drugs, which is often limited due to toxicity and severe adverse effects. Areas covered: This review summarizes the literature on the mechanism of action, clinical efficacy and safety of dupilumab, a monoclonal antibody that targets the α-subunit of the interleukin-4 receptor (IL-4Rα) leading to the inhibition of both the IL-4 and IL-13 pathways...
February 6, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28162009/mite-allergens
#8
Luis Caraballo
No abstract text is available yet for this article.
February 6, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28121191/topical-immunotherapy-with-diphencyprone-dpcp-for-in-transit-and-unresectable-cutaneous-melanoma-lesions-an-inaugural-canadian-series
#9
Carrie Yeung, Teresa M Petrella, Frances C Wright, Wadid Abadir, Nicole J Look Hong
BACKGROUND: Diphencycprone (DPCP) is an immune contact sensitizer applied to melanoma lesions. Early studies show favorable efficacy. We present the first North-American series of patients treated with DPCP. METHODS: A single center retrospective study of patients with in-transit or unresectable melanoma lesions treated with DPCP from December 1,2014 to December 31,2015 was completed. Primary objectives were response rate and toxicity. Secondary objective was health-related quality of life assessment with the Functional Assessment of Cancer Therapy-Melanoma (FACT-M) questionnaire...
February 6, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28116918/standard-and-biological-treatment-in-large-vessel-vasculitis-guidelines-and-current-approaches
#10
Francesco Muratore, Nicolò Pipitone, Carlo Salvarani
Giant cell arteritis and Takayasu arteritis are the two major forms of idiopathic large vessel vasculitis. High doses of glucocorticoids are effective in inducing remission in both conditions, but relapses and recurrences are common, requiring prolonged glucocorticoid treatment with the risk of the related adverse events. Areas covered: In this article, we will review the standard and biological treatment strategies in large vessel vasculitis, and we will focus on the current approaches to these diseases. Expert commentary: The results of treatment trials with conventional immunosuppressive agents such as methotrexate, azathioprine, mycophenolate mofetil, and cyclophosphamide have overall been disappointing...
February 6, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28164726/inhibition-of-b-cell-activating-factor-baff-in-the-management-of-systemic-lupus-erythematosus-sle
#11
William Stohl
The anti-BAFF monoclonal antibody, belimumab, was approved 5+ years ago by the US Food and Drug Administration for the treatment of adult SLE patients. Although BAFF is now a proven therapeutic target in SLE, the limited clinical efficacy both in the clinical trials setting and in "real-life" experience begs for further therapeutic improvement. Areas covered: In addition to belimumab, three other BAFF antagonists (atacicept, blisibimod, tabalumab) that biologically differ from belimumab are being or have been evaluated in SLE late-stage clinical trials...
February 4, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28164724/jak-inhibition-in-inflammatory-bowel-disease
#12
Pablo Olivera, Silvio Danese, Laurent Peyrin-Biroulet
Current available treatments for inflammatory bowel disease (IBD) have some limitations and new options are needed. Several new molecules are being tested for the treatment of IBD and other immune-mediated inflammatory diseases. Among them, Janus kinase (JAK) inhibitors seem to have the lead, since tofacitinib has received regulatory approval in 2012 for the treatment of rheumatoid arthritis, and also it has shown a favorable risk-benefit ratio in phase 3 studies for ulcerative colitis, both in anti-TNF naïve and anti-TNF experienced patients...
February 4, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28162007/clinical-use-of-adjuvants-in-allergen-immunotherapy
#13
L Klimek, C B Schmidt-Weber, M F Kramer, M A Skinner, M D Heath
Introduction Allergen-specific Immunotherapy (AIT) is the only available treatment aimed to tackle the underlying causes of allergy. The active components of subcutaneous vaccines traditionally consist of natural or modified allergen extracts which can be combined with adjuvant platforms. In recent years new targets have been further developed in an attempt to raise the safety and efficacy profile of AIT. Areas Covered In this review, we discuss the desirable attributes of adjuvants and delivery systems from empiricism to rational design, for current and future clinical applications in AIT...
February 4, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28162005/the-clinical-significance-of-complete-class-switching-defect-in-ataxia-telangiectasia-patients
#14
Saleh Ghiasy, Leila Parvaneh, Gholamreza Azizi, Ghazal Sadri, Majid Zaki Dizaji, Hassan Abolhassani, Asghar Aghamohammadi
OBJECTIVES: Ataxia telangiectasia (AT) is a primary immunodeficiency associated with recurrent infections. We aimed to investigate clinical and immunological classification in AT patients who suffer from a different spectrum of humoral immune defects. METHODS: AT patients were categorized according to the ability of class switching and patients with hyper IgM (HIgM) profile were defined as class switching defect (CSD). RESULTS: Serum immunoglobulin profile in 66 AT patients showed normal immunoglobulin level (22...
February 4, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28092215/therapeutic-implications-from-the-pathogenesis-of-raynaud-s-phenomenon
#15
Ariane L Herrick
Raynaud's phenomenon (RP) can be either primary (idiopathic) or secondary to a number of different diseases/conditions, when vasopasm can be superimposed upon structural vascular abnormality or a hyperviscosity state and may then lead to severe ischaemia with tissue damage. Treatment must be tailored to the individual. Areas covered: This review discusses how increased understanding of the pathogenesis of RP has driven and is driving new approaches to therapy, and how we are now better able to predict which patients presenting with RP are likely to have an underlying disease requiring specific intervention...
February 3, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28145784/commensal-microbiota-as-a-potential-trigger-of-autoimmune-uveitis
#16
Reiko Horai, H Nida Sen, Rachel R Caspi
No abstract text is available yet for this article.
February 1, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28140700/adalimumab-for-the-treatment-of-uveitis
#17
Kara C LaMattina, Debra A Goldstein
Adalimumab, an inhibitor of tumor necrosis factor-alpha (TNFα), is the only systemic non-corticosteroid agent which has been approved by the US Food and Drug Administration (FDA) for the treatment of non-infectious uveitis. Areas covered:The aim of this review is to summarize the research which demonstrated the effectiveness of adalimumab in the treatment of intraocular inflammation and helped to establish its side effect profile, ultimately leading to its FDA approval. Expert commentary:Adalimumab is a useful second-line agent in the treatment of non-infectious uveitis...
January 31, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28064550/the-role-of-il-4-in-psoriasis
#18
Matthias Hahn, Kamran Ghoreschi
No abstract text is available yet for this article.
January 16, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28067059/il-23-blockade-for-crohn-s-disease-next-generation-of-anti-cytokine-therapy
#19
Federica Furfaro, Daniela Gilardi, Mariangela Allocca, Clelia Cicerone, Carmen Correale, Gionata Fiorino, Silvio Danese
Adaptive immunity in intestinal inflammation may play a key role in the pathogenesis of Crohn's disease. In particular, interleukin (IL)-23 may be a key mediator in chronic intestinal inflammation by inducing the differentiation of naïve CD4+ T cells into Th17, with the production of several pro-inflammatory cytokines. Furthermore, IL-23 induces interferon-γ (IFN- γ) production from activated T cells, a critical cytokine in innate and adaptive immunity against infections. Areas covered: We aim to review the available data from literature regarding the role of IL-23, with a more specific focus on the recent progresses in the therapeutic modulation of this cytokine...
January 9, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28064547/a-systematic-approach-to-autoinflammatory-syndromes-a-spelling-booklet-for-the-beginner
#20
Donato Rigante
Hallmark of autoinflammatory syndromes (AIS) is the periodic recurrence of 'sterile' inflammatory attacks characterized by fever and organ- or tissue-specific inflammation. Basic research projects over the last two decades have boosted our understanding of pathological pathways, mainly involving interleukin (IL)-1 biosynthesis, and also revealed that their dysregulation results from genetically-heterogeneous inborn errors of innate immunity and leads to multiple inflammatory phenotypes. Starting from the evidence of poor response to IL-1 inhibitors of some patients with multi-organ inflammation, further research studies have disclosed a crucial role for nuclear factor (NF)-κB and type I interferon (IFN) in specific AIS...
January 9, 2017: Expert Review of Clinical Immunology
journal
journal
41324
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"